儿科患者遗传性抗血缺乏症:病理生理学,临床特征,诊断和抗血替代疗法
George M Rodgers1, Wilton I Rodriguez2
1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah Medical Center, Salt Lake City, UT, USA.
概括
遗传性抗血缺乏症 (hATD) 会增加血栓形成的风险. 一种新的FDA批准的抗血素缩物为儿科hATD患者提供了第一个向治疗,改善了管理策略.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
背景情况:
- 反凝血素 (AT) 对于抗凝血至关重要,它调解肝素的作用,并防止高凝血状态.
- 由SERPINC1突变引起的遗传AT缺乏症 (hATD) 是一种严重的血栓友症,具有高终身静脉血栓栓塞 (VTE) 风险.
- 儿童hATD管理历史上依赖于非标签的成人数据来使用抗血素缩物 (ATc).
研究的目的:
- 审查当前对儿科hATD的临床理解.
- 综合基于证据的策略,以优化儿科hATD的AT治疗.
- 为了解决最近FDA批准ATc用于儿科的含义.
主要方法:
- 临床研究和指导方针的文献综述.
- 分析抗血缩剂的疗效和安全性数据.
- 专家意见和共识建议的综合.
主要成果:
- 在儿童和成人群体中,hATD显著增加了VTE风险.
- 美国食品和药物管理局 (FDA) 对ATc的扩大指示提供了第一个专门批准用于儿科hATD的治疗方法.
- 优化AT治疗策略对于管理这种高风险儿科患者群体至关重要.
结论:
- 批准ATc用于儿科hATD标志着治疗的重大进步.
- 基于证据的AT治疗优化对于改善儿科hATD的结果至关重要.
- 进一步的研究可能会对患有hATD的儿科患者的AT治疗方案进行改进.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Venous Thrombosis III: Interprofessional Care
392
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
392
Disorders of Hemostasis
2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
258
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258
Pharmacokinetics in Pediatric Patients: Drug Excretion
289
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
344
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
344


